SEARCH:

CV301 in Bladder Cancer

Bavarian Nordic has entered a collaboration with Roche to evaluate the combination of CV301 and Tecentriq® (atezolizumab), Roche’s FDA-approved PD-L1 inhibitor, in bladder cancer. Roche will provide the drug for the study.